Research paperEvaluation of collagen/hydroxyapatite electrospun layers loaded with vancomycin, Gentamicin (cas 1403-66-3) and their combination: Comparison of release kinetics, antimicrobial activity and cytocompatibility
-
Add time:09/10/2019 Source:sciencedirect.com
The aim of this study was to develop a biodegradable nanostructured electrospun layer based on collagen (COL), hydroxyapatite nanoparticles (HA), vancomycin hydrochloride (V), Gentamicin (cas 1403-66-3) sulphate (G) and their combination (VG) for the treatment of prosthetic joint infections and the prevention of infection during the joint replacement procedure. COL/HA layers containing different amounts of HA (0, 5 and 15 wt%) were tested for the in vitro release kinetics of antibiotics, antimicrobial activity against MRSA, gentamicin-resistant Staphylococcus epidermidis and Enterococcus faecalis isolates and cytocompatibility using SAOS-2 bone-like cells. The results revealed that the COL/HA layers released high concentrations of vancomycin and gentamicin for 21 days and performed effectively against the tested clinically-relevant bacterial isolates. The presence of HA in the collagen layers was found not to affect the release kinetics of the vancomycin from the layers loaded only with vancomycin or its combination with gentamicin. Conversely, the presence of HA slowed down the release of gentamicin from the COL/HA layers loaded with gentamicin and its combination with vancomycin. The combination of both antibiotics exerted a positive effect on the prolongation of the conversion of vancomycin into its degradation products. All the layers tested with different antibiotics exhibited potential antibacterial activity with respect to both the tested staphylococci isolates and enterococci. The complemental effect of vancomycin was determined against both gentamicin-resistant Staphylococcus epidermidis and Enterococcus faecalis in contrast to the application of gentamicin as a single agent. This combination was also found to be more effective against MRSA than is vancomycin as a single agent. Importantly, this combination of vancomycin and gentamicin in the COL/HA layers exhibited sufficient cytocompatibility to SAOS-2, which was independent of the HA content. Conversely, only gentamicin caused the death of SAOS-2 independently of HA content and only vancomycin stimulated SAOS-2 behaviour with an increased concentration of HA in the COL/HA layers. In conclusion, COL/HA layers with 15 wt% of HA impregnated with vancomycin or with a combination of vancomycin and gentamicin offer a promising treatment approach and the potential to prevent infection during the joint replacement procedures.
We also recommend Trading Suppliers and Manufacturers of Gentamicin (cas 1403-66-3). Pls Click Website Link as below: cas 1403-66-3 suppliers
Prev:Electrospinning of silica nanoparticles-entrapped nanofibers for sustained Gentamicin (cas 1403-66-3) release
Next:Antifungal antibiotic Hamycin (cas 1403-71-0) increases susceptibility of Candida albicans to phagocytosis by murine macrophages) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Electrospinning of silica nanoparticles-entrapped nanofibers for sustained Gentamicin (cas 1403-66-3) release09/09/2019
- Microbicidal Gentamicin (cas 1403-66-3)-alginate hydrogels09/08/2019
- Synthesis of Gentamicin (cas 1403-66-3)-grafted-chitosan with improved solubility and antibacterial activity09/07/2019
- Controllable delivery from Gentamicin (cas 1403-66-3) loaded polycaprolactone/grafted silica nanoparticles composite mats09/06/2019
- Improving Gentamicin (cas 1403-66-3) B and Gentamicin (cas 1403-66-3) C1a production by engineering the glycosyltransferases that transfer primary metabolites into secondary metabolites biosynthesis09/05/2019
- Original articleEffect of Withania somnifera on Gentamicin (cas 1403-66-3) induced renal lesions in rats09/04/2019
- Intratympanic mixture Gentamicin (cas 1403-66-3) and dexamethasone versus dexamethasone for unilateral Meniere's disease09/03/2019
- Overproduction of Gentamicin (cas 1403-66-3) B in industrial strain Micromonospora echinospora CCTCC M 2018898 by cloning of the missing genes genR and genS09/02/2019
- Original ArticleStandard-dose Gentamicin (cas 1403-66-3) does not increase risk of patent ductus arteriosus09/01/2019